Call Scheduled for Monday, March 19, 2018 at 4:30pm Eastern Time.
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, will report financial results for the year ended December 31, 2017 and host a conference call and webcast at 4:30pm Eastern Time on Monday, March 19, 2018.
| Conference Call & Webcast | ||||||
| Monday, March 19th @ 4:30pm Eastern Time | ||||||
| Domestic: | 800-289-0438 | |||||
| International: | 323-994-2083 | |||||
| Passcode: | 1979356 | |||||
| Webcast: | http://public.viavid.com/index.php?id=128779 | |||||
| Replays available through April 2: | ||||||
| Domestic: | 844-512-2921 | |||||
| International: | 412-317-6671 | |||||
| Conference ID: | 1979356 | |||||
| | ||||||
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
Steve@AIT-Pharm.com
Bob Yedid
LifeSci Advisors, LLC
Bob@LifeSciAdvisors.com
(646) 597 6989